Diagnose of pancreatic cancer needs a lot of spending money for both healthcare workers and patients, and limitations. The best biomarker used up to this day has been CA19-9. As well known by the literature, novel studies investigating inflammatory biomarkers in pancreatic adeno carcinoma, as an alternative to CA19-9. Platelets constitute an important source of agents associated with inflammatory markers. Especially, hematological parameters that triggered by inflammation have been concentrated on by physicians, in cancer-related diseases. However, the missing point of the recent researches has been platelet distribution width. Its potential will change the angle of view to CA19-9 used in diagnose and follow-up of the resectable pancreatic adeno carcinoma.